



In Search of Excellence

Orion Pharma Limited

Registered Office: Orion House, 153-154 Tejgaon I/ A,
Dhaka - 1208

Un-Audited 3rd Quarterly (Q3) Financial Statements

This is to inform all concerned that, in Board Meeting held on April 29, 2024 at 3:30 p.m. in the registered office at Orion House, 153-154 Tejgaon I/ A, Dhaka - 1208, the Board of Directors of Orion Pharma Limited has adopted its Un- audited 3rd Quarterly (Q3) Financial Statements for the period ended March 31, 2024:

For the Period		July-March 2024	July-March 2023	January- March 2024	January- March 2023
Consolidated Earnings Per Share (EPS) - Q3	:	BDT 1.65	BDT 2.44	BDT 0.42	BDT 0.53
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q3	:	BDT 3.09	BDT 6.85	--	--
Particulars		March 31, 2024		June 30, 2023	
Consolidated Net Asset Value (NAV) per Share -Q3 (Including Revaluation Surplus)	:	BDT 93.01		BDT 88.99	
Consolidated Net Asset Value (NAV) per Share -Q3 (Excluding Revaluation Surplus)	:	BDT 85.21		BDT 81.15	

Dated: April 29, 2024
Tejgaon, Dhaka

By the order of the Board
Sd/-
Md. Ferdous Jaman
Company Secretary